BioHarvest launches VINIA chewable supplement
BioHarvest launches VINIA Daily Chews, expanding its first Botanical Synthesis consumer product into a chewable format designed to reach broader demographics.
Rhea-AI Filing Summary
BIOHARVEST SCIENCES INC. (BHST) reported the commercial launch of single-dose VINIA® Daily Chews, a new chewable format of its proprietary red-grape cell composition VINIA. The product extends VINIA beyond capsules and is intended to broaden the brand’s addressable market and daily usage occasions.
Each individually packaged Daily Chew delivers 400 mg of VINIA, matching the company’s capsule dosage, and includes 6 mg of piceid resveratrol, a daily amount described as clinically shown to increase arterial dilation and improve blood flow. Management states that early feedback on the chewable format indicates strong engagement and retention relative to internal expectations for a new delivery form.
BioHarvest highlights the launch as further evidence of its Botanical Synthesis platform and its strategy to operate both as a CDMO partner and as a developer of proprietary compositions. The company notes that VINIA’s format expansion provides a live example for potential CDMO customers of how plant-cell compositions can move from development through scaled manufacturing into differentiated consumer products.
Positive
- None.
Negative
- None.
Key Figures
VINIA per chew: 400 mg of VINIA
Piceid resveratrol per chew: 6 mg of piceid resveratrol
Gummy/chewable supplements market size: $24.4 billion
+3 more
6 metrics
VINIA per chew
400 mg of VINIA
Amount of VINIA delivered by each single-dose VINIA Daily Chew
Piceid resveratrol per chew
6 mg of piceid resveratrol
Daily dosage per VINIA Daily Chew described as clinically shown to affect blood flow
Gummy/chewable supplements market size
$24.4 billion
Estimated global gummy/chewable supplements market in 2025
Gummy/chewable supplements CAGR
14.4%
Projected CAGR for the global gummy/chewable supplements market through 2030
VINIA dosage equivalence
400 mg
Daily Chew VINIA amount matches daily VINIA amount in capsule format
News release date
September 15, 2026
Date of the VINIA Daily Chews launch announcement
Key Terms
Botanical Synthesis, Contract Development and Manufacturing Organization, piceid resveratrol, oral transmucosal delivery, +2 more
6 terms
Botanical Synthesis technical
"BioHarvest, a Botanical Synthesis company developing and manufacturing proprietary plant-based"
Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.
Contract Development and Manufacturing Organization financial
"applying its Botanical Synthesis capabilities as a Contract Development and Manufacturing Organization"
A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.
piceid resveratrol medical
"Each individually packaged VINIA Daily Chew contains 400 mg of VINIA and 6 mg of piceid resveratrol"
Piceid resveratrol is a natural compound where a sugar molecule is attached to resveratrol, a plant molecule often linked to antioxidant effects; think of it as resveratrol with a sugar coat that can change how the body handles it. Investors care because this form can affect how much of the active ingredient reaches the body, influencing the value of supplements, drug development programs, and regulatory assessments tied to safety, efficacy, and market demand.
oral transmucosal delivery medical
"the chewable format also provides an opportunity to explore oral transmucosal delivery"
A drug-delivery method where a medicine is placed in the mouth and absorbed directly through the mucous membranes (for example under the tongue or against the cheek) instead of being swallowed. It often produces faster bloodstream absorption and can avoid breakdown by the digestive system, like holding a lozenge that dissolves against the cheek; for investors, this affects how quickly a product works, its patient convenience, formulation complexity, regulatory testing, and commercial appeal.
polyphenols medical
"delivery may affect the absorption and systemic exposure of resveratrol and other grape-derived polyphenols"
Polyphenols are naturally occurring compounds found in plants—such as fruits, tea, wine and cocoa—that often act like tiny shields against damage inside the body. Investors care because these compounds drive consumer demand for foods, beverages and supplements marketed for health benefits; evidence, regulatory scrutiny, or shifting trends around their effectiveness can directly affect product sales, brand value and profit forecasts. Think of polyphenols as the ingredient on a label that can boost or hurt a product’s appeal.
full-spectrum plant compounds technical
"approach to consistent, full-spectrum plant compounds at scale"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BIOHARVEST SCIENCES INC. (BHST) announce in this Form 6-K?
BHST announced the launch of single-dose VINIA Daily Chews, a chewable format of its proprietary red-grape cell composition VINIA, intended to expand the product’s demographics, usage occasions, and support its Botanical Synthesis and CDMO positioning.
How much VINIA and resveratrol does each VINIA Daily Chew from BHST contain?
Each VINIA Daily Chew contains 400 mg of VINIA and 6 mg of piceid resveratrol. The company states this daily dosage has been clinically shown to increase arterial dilation and improve blood flow, accompanied by the standard regulatory disclaimer in the release.
How does the new VINIA Daily Chews format fit into BHST’s Botanical Synthesis strategy?
The chewable VINIA format is presented as a live commercial example of Botanical Synthesis, showing how BioHarvest can take a plant-cell composition from development through scaled manufacturing into multiple consumer formats, supporting its role as a Contract Development and Manufacturing Organization (CDMO).
What market opportunity does BHST reference for VINIA Daily Chews?
BHST cites an estimate that the global gummy/chewable supplements market is about $24.4 billion in 2025, projected to grow at a 14.4% CAGR through 2030, framing demand for convenient formats that can reach demographics beyond traditional capsule users.
Where can consumers purchase BHST’s VINIA Daily Chews?
VINIA Daily Chews in the single-dose format are stated to be available for purchase on www.vinia.com, alongside the existing VINIA capsule offerings.
What forward-looking cautions does BHST give about VINIA Daily Chews?
BHST notes there is no guarantee the single-dose option will generate revenue, reach new segments, or expand VINIA’s addressable market. It highlights that commercialization depends on consumer preferences, advertising budgets, and other uncertain factors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
